Lupus nephritis (LN) is a chronic and devastating complication of systemic lupus erythematosus. Despite advances in our understanding of LN and the availability of effective therapies, LN remains a difficult clinical problem, and progression to end stage renal disease remains a significant challenge. Though the advent of biologics has revolutionized the treatment of many rheumatological conditions, and several clinical trials of biologics have been conducted in LN, the promise of biologics remains unfulfilled. The experience gained from these initial clinical trials can help tailor approaches in future clinical trials, and the lessons learned can be applied to find a cure for this condition.
WardMMPyunEStudenskiS. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med1996; 156: 1337–1344.
3.
HoussiauFAVasconcelosCD’CruzD. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long‐term followup of patients in the Euro‐Lupus Nephritis Trial. Arthritis Rheum2004; 50: 3934–3940.
4.
HahnBHMcMahonMAWilkinsonA. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res2012; 64: 797–808.
5.
KasitanonNMagderLSPetriM. Predictors of survival in systemic lupus erythematosus. Medicine2006; 85: 147–156.
6.
AlarconGSMcGwinGJrPetriMReveilleJDRamsey-GoldmanRKimberlyRP. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus2002; 11: 95–101.
7.
van VollenhovenRFMoscaMBertsiasG. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis2014; 73: 958–967.
8.
GladmanDDUrowitzMBRahmanPIbanezDTamLS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol2003; 30: 1955–1959.
9.
ThamerMHernanMAZhangYCotterDPetriM. Prednisone, lupus activity, and permanent organ damage. J Rheumatol2009; 36: 560–564.
10.
VandepapelièreJAydinSCosynsJ-PDepresseuxGJadoulMHoussiauF. Prognosis of proliferative lupus nephritis subsets in the Louvain Lupus Nephritis inception Cohort. Lupus2014; 23: 159–165.
ChanTM. Treatment of severe lupus nephritis: the new horizon. Nature Rev Nephrol2015; 11: 46–61.
13.
WaldmanMAppelG. Update on the treatment of lupus nephritis. Kidney Int2006; 70: 1403–1412.
14.
LightstoneE. I97. Managing lupus nephritis in the era of biologic therapies. Rheumatology2015; 54: i18–i.
15.
Gómez-PuertaJAFeldmanCHAlarcónGSGuanHWinkelmayerWCCostenbaderKH. Racial and ethnic differences in mortality and cardiovascular events among patients with end‐stage renal disease due to lupus nephritis. Arthritis Care Res2015; 67: 1453–1462.
16.
ClowseMEGrotegutC. Racial and ethnic disparities in the pregnancies of women with systemic lupus erythematosus. Arthritis Care Res2016.
17.
LiuYAndersHJ. Lupus nephritis: from pathogenesis to targets for biologic treatment. Nephron Clin Pract2014; 128: 224–231.
18.
HoldsworthSRGanP-YKitchingAR. Biologics for the treatment of autoimmune renal diseases. Nat Rev Nephrol2016; 12: 217–231.
19.
CrowMK. Collaboration, genetic associations, and lupus erythematosus. N Engl J Med2008; 358: 956–961.
20.
AndersHJFogoAB. Immunopathology of lupus nephritis. Semin Immunopathol2014; 36: 443–459.
21.
RovinBHFurieRLatinisK. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum2012; 64: 1215–1226.
22.
FurieRNichollsKChengT-T. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheum2014; 66: 379–389.
23.
AskanaseAByronMKeyes-ElsteinL. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheum2014; 66: 3096–3104.
24.
MyslerEFSpindlerAJGuzmanR. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum2013; 65: 2368–2379.
25.
GinzlerEMWaxSRajeswaranA. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther2012; 14: 1–7.
26.
van VollenhovenRAranowCRovinB. OP0047 a phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of sirukumab in patients with active lupus nephritis. Ann Rheum Dis2014; 73: 78–78.
27.
JayneDChanTMBarkayHWeissRWofsyD. A randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care. Ann Rheum Dis2013; 72: 164–164.
28.
LuTYTNgKPCambridgeG. A retrospective seven‐year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: the first fifty patients. Arthritis Care Res2009; 61: 482–487.
29.
LindholmCBörjesson-AspKZendjanchiKSundqvistA-CTarkowskiABokarewaM. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol2008; 35: 826–833.
30.
SfikakisPBoletisJLionakiS. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down‐regulation of the T cell costimulatory molecule CD40 ligand: an open‐label trial. Arthritis Rheum2005; 52: 501–513.
31.
TerrierBAmouraZRavaudP. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum2010; 62: 2458–2466.
32.
JónsdóttirTGunnarssonIMourãoAFLuTYvan VollenhovenRFIsenbergD. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology2010; 49: 1502–1504.
33.
BezalelSAsherIElbirtDSthoegerZM. Novel biological treatments for systemic lupus erythematosus: current and future modalities. Israel Med Assoc J2012; 14: 508–514.
34.
KamalAKhamashtaM. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev2014; 13: 1094–1101.
35.
CarterLMIsenbergDAEhrensteinMR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum2013; 65: 2672–2679.
36.
FinckBKLinsleyPSWofsyD. Treatment of murine lupus with CTLA4Ig. Science1994; 265: 1225–1227.
37.
MerrillJTBurgos-VargasRWesthovensR. The efficacy and safety of abatacept in patients with non–life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum2010; 62: 3077–3087.
38.
WofsyDHillsonJLDiamondB. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum2013; 65: 1586–1591.
39.
IsenbergDARahmanA. Systemic lupus erythematosus in 2013: taking a closer look at biologic therapy for SLE. Nat Rev Rheumatol2014; 10: 71–72.
40.
DooleyMHoussiauFAranowC. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus2013; 22: 63–72.
41.
RoschkeVSosnovtsevaSWardCD. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol2002; 169: 4314–4321.
42.
FurieRACashJMCroninME. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol2001; 28: 257–265.
43.
CardielMHTumlinJAFurieRAWallaceDJJohTLinnikMD. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum2008; 58: 2470–2480.
44.
Alarcón-SegoviaDTumlinJAFurieRA. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum2003; 48: 442–454.
45.
LinnikMDHuJZHeilbrunnKR. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum2005; 52: 1129–1137.
46.
BoumpasDTFurieRManziS. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum2003; 48: 719–727.
47.
AlexanderTSarfertRKlotscheJ. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis2015; 74: 1474–1478.
48.
DooleyMAJayneDGinzlerEM. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med2011; 365: 1886–1895.
49.
Dall’EraMStoneDLevesqueVCisternasMWofsyD. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res2011; 63: 351–357.
50.
FurieRToderKZapantisE. Lessons learned from the clinical trials of novel biologics and small molecules in lupus nephritis. Semin Nephrol2015; 35: 509–520.
51.
HoussiauFAVasconcelosCD’CruzD. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum2002; 46: 2121–2131.
52.
Dall’EraMCisternasMGSmilekDE. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheum2015; 67: 1305–1313.
53.
StoneJHMerkelPASpieraR. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med2010; 363: 221–232.
54.
NasrallahMPouliotYHartmannB. Reanalysis of the rituximab in ANCA-associated vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment. Arthritis Res Ther2015; 17: 262–262.
